Company Description
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.
The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.
It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions.
In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials.
Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners.
It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | Canada |
| Founded | 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 208 |
| CEO | Bret Christensen |
Contact Details
Address: 12340 El Camino Real San Diego, California 92130 United States | |
| Phone | 858-450-4222 |
| Website | dermtech.com |
Stock Details
| Ticker Symbol | DMTKQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651944 |
| CUSIP Number | G2379F124 |
| ISIN Number | US24984K1051 |
| Employer ID | 84-2870849 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Bret Christensen | President, Chief Executive Officer and Director |
| Kevin Sun M.B.A. | Chief Financial Officer, Treasurer and Secretary |
| Ray Akhavan Esq., J.D. | General Counsel |
| William W. Zondler | Chief Information Officer |
| Steve E. Kunszabo | Senior Director of Investor Relations |
| Jennifer Eilemberg | Chief Compliance Officer |
| Dr. Burkhard Jansen M.D. | Chief Medical Affairs Officer |
| Dr. Loren Clarke M.D. | Chief Medical Officer |
| Dr. Steven Stone Ph.D. | Senior Vice President of Research and Development |
| Mark Aguillard | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | 25-NSE | Filing |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |
| May 17, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 10, 2024 | 8-K | Current Report |
| Apr 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 26, 2024 | 10-K/A | [Amend] Annual report |
| Apr 18, 2024 | 8-K | Current Report |